ALKERMES, INC. for ALKERMES, INC.

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Health Issues HCR

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act

Contacted: Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (119th), S. 464 (119th), H.R. 2163 (119th), H.R. 1414 (119th), H.R. 946 (119th)

Alcohol and Drug Abuse ALC

Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); Justice, Dept of (DOJ); Executive Office of the President (EOP); Veterans Affairs, Dept of (VA)

Bills named: H.R. 4030 (119th)

Tariff (miscellaneous tariff bills) TAR

Policies impacting pharmaceutical distribution and manufacturing

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP)